Hemay 005Alternative Names: Hemay005
Latest Information Update: 19 Jan 2017
At a glance
- Originator Tianjin Hemay Biotech
- Class Antipsoriatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
Most Recent Events
- 01 Dec 2016 Phase-I clinical trials in Psoriasis (In volunteers) in China (PO) (NCT03007810)